Fennec Pharmaceuticals (FENC) Income from Non-Controlling Interests (2011 - 2019)
Fennec Pharmaceuticals' (FENC) quarterly Income from Non-Controlling Interests came in at $17000.0 in Q2 2019, up 41.67% on a QoQ basis from $12000.0 in Q1 2019.
Powered by 
Analysis
Fennec Pharmaceuticals (FENC) Income from Non-Controlling Interests (2011 - 2019) Analysis & Trends
Fennec Pharmaceuticals (FENC) has 3 years of Income from Non-Controlling Interests data on file, last reported at $17000.0 in Q2 2019.
- Quarterly Income from Non-Controlling Interests changed N/A year-over-year to $17000.0 in Q2 2019, while the trailing twelve-month figure through Dec 2012 was $66.0 million (changed 0.0% YoY) and the FY2012 annual result came in at $66.0 million, changed 0.0% from the prior year.
- Income from Non-Controlling Interests rose to $17000.0 in Q2 2019, from $12000.0 in the prior quarter.
- In the past five years, Income from Non-Controlling Interests ranged from a high of $17000.0 in Q2 2019 to a low of $12000.0 in Q1 2019.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 63.60 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Fennec Pharmaceuticals | 432.85 Mn | 391.60 Mn | 17.15 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2019 | 17,000.00 |
| Mar 31, 2019 | 12,000.00 |
| Dec 31, 2012 | 65.95 Mn |
| Dec 31, 2011 | 65.95 Mn |